{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:22Z","timestamp":1792441762271,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0388-0","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T12:00:30Z","timestamp":1457611230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs"],"prefix":"10.1186","volume":"11","author":[{"given":"Katarzyna","family":"Kolasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof M.","family":"Zwolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Kalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Hermanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"388_CR1","unstructured":"EUnetHTA. http:\/\/www.eunethta.eu\/faq\/Category%201-0#t287n73 . Accessed November 2015."},{"issue":"Suppl. 5","key":"388_CR2","first-page":"S1","volume":"97","author":"T Culyer","year":"2014","unstructured":"Culyer T. Where are the Limits of Cost-Effectiveness Analysis and Health Technology Assessment? J Med Assoc Thai. 2014;97 Suppl 5:S1\u20132.","journal-title":"J Med Assoc Thai"},{"issue":"4","key":"388_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11539470-000000000-00000","volume":"3","author":"JG Dolan","year":"2010","unstructured":"Dolan JG. Multi-criteria clinical decision support: A primer on the use of multiple criteria decision making methods to promote evidence-based, patient-centered healthcare. Patient. 2010;3(4):229\u201348.","journal-title":"Patient"},{"key":"388_CR4","unstructured":"Devlin NJ, Sussex J. Incorporating multiple criteria in HTA, methods and processes. Office of Health Economics. 2011; 1\u201360. ISBN: 978-1-899040-98-8. https:\/\/www.ohe.org\/publications\/incorporating-multiple-criteria-hta-methods-and-processes . Access 6 March 2016."},{"key":"388_CR5","volume-title":"Series: International Series in Operations Research & Management Science, Vol. 78","author":"J Figueira","year":"2005","unstructured":"Figueira J, Greco S, Ehrgott M. Multiple criteria decision analysis: state of the art surveys. In: Series: International Series in Operations Research & Management Science, Vol. 78. New York, USA: Springer Science + Business Media; 2005."},{"key":"388_CR6","unstructured":"International Society for Pharmacoeconomics and Outcomes Research (ISPOR). http:\/\/www.ispor.org\/taskforces\/multi-criteria-decision-analysis-grp.asp ."},{"key":"388_CR7","unstructured":"COMP report to the commission in relation to article 10 of regulation 141\/2000 on orphan medicinal products, EMEA\/35218\/2005. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/04\/WC500089638.pdf . Accessed January 2015."},{"key":"388_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-9-62","volume":"9","author":"E Picavet","year":"2014","unstructured":"Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9:62.","journal-title":"Orphanet J Rare Dis"},{"key":"388_CR9","unstructured":"EvaluatePharma Orphan drug report 2014. http:\/\/info.evaluategroup.com\/rs\/evaluatepharmaltd\/images\/2014OD.pdf . Accessed March 2015."},{"key":"388_CR10","unstructured":"International rare diseases research consortium (IRDiRC). http:\/\/www.irdirc.org\/the-european-commission-publishes-its-implementation-report-on-rare-diseases-europes-challenges-and-council-recommendations\/ . Accessed November 2015."},{"key":"388_CR11","unstructured":"EURORDIS Rare Diseases Europe. http:\/\/www.eurordis.org\/content\/moca . Accessed November 2015."},{"key":"388_CR12","unstructured":"European Commission. Transparent value framework (Platform on access to medicines in Europe - Working Group on Mechanism of coordinated access to orphan medicinal products), 19.11.2014. http:\/\/ec.europa.eu\/DocsRoom\/documents\/7631?locale=en . Accessed November 2015."},{"issue":"5","key":"388_CR13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14737167.2014.940903","volume":"14","author":"K Kolasa","year":"2014","unstructured":"Kolasa K. Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector? Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):751\u201362.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"388_CR14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.healthpol.2014.09.015","volume":"118","author":"K Kolasa","year":"2014","unstructured":"Kolasa K, Dohnalik J, Borek E, Siemiatkowski M, Scibiorski C. The paradox of public participation in the healthcare in Poland - what citizens want, and what they think. Health Policy. 2014;118(2):159\u201365.","journal-title":"Health Policy"},{"issue":"4","key":"388_CR15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1017\/S0266462313000482","volume":"29","author":"K Kolasa","year":"2013","unstructured":"Kolasa K, Annemans L, Lees M. Assessment of the attitudes of the general public towards supplementary criteria to be used in P&R decision making process in Poland. Int J Technol Assess Health Care. 2013;29(4):443\u20139.","journal-title":"Int J Technol Assess Health Care"},{"key":"388_CR16","unstructured":"OECD Health Statistic 2014, Poland. http:\/\/www.oecd.org\/els\/health-systems\/Briefing-Note-POLAND-2014.pdf . Accessed January 2015."},{"issue":"3","key":"388_CR17","first-page":"83","volume":"1","author":"D Tordrup","year":"2014","unstructured":"Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Diseases and Orphan Drugs. An Int J Public Health. 2014;1(3):83\u201397.","journal-title":"An Int J Public Health"},{"key":"388_CR18","unstructured":"The Agency for Health Technology Assessment (Agencja Oceny Technologii Medycznych, AOTM). www.aotm.gov.pl . Accessed November 2015."},{"key":"388_CR19","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4615-1495-4","volume-title":"Multiple Criteria Decision Analysis: An Integrated Approach","author":"V Belton","year":"2002","unstructured":"Belton V, Stewart TJ. Multiple Criteria Decision Analysis: An Integrated Approach. Boston: Kluwer Academic Publishers; 2002."},{"key":"388_CR20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00228-012-1423-2","volume":"69","author":"R Joppi","year":"2013","unstructured":"Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69:1009\u201324.","journal-title":"Eur J Clin Pharmacol"},{"key":"388_CR21","unstructured":"Orphanet Report Series - Lists of medicinal products for rare diseases in Europe. 2014. page 41, classification by date of MA in descending order. http:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/list_of_orphan_drugs_in_europe.pdf . Accessed January 2015."},{"key":"388_CR22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jval.2013.10.002","volume":"16","author":"J Sussex","year":"2013","unstructured":"Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16:1163\u20139.","journal-title":"Value Health"},{"issue":"4","key":"388_CR23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2125.2010.03877.x","volume":"71","author":"AG Dupont","year":"2011","unstructured":"Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71(4):488\u201396.","journal-title":"Br J Clin Pharmacol"},{"key":"388_CR24","unstructured":"Herper M. The world\u2019s most expensive drugs. Forbes, 2010. http:\/\/www.forbes.com\/2010\/02\/19\/expensive-drugs-cost-business-healthcare-rare-diseases.html . Accessed January 2015."},{"issue":"suppl S","key":"388_CR25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.18553\/jmcp.2008.14.S4-A.3","volume":"14","author":"SD Sullivan","year":"2008","unstructured":"Sullivan SD. The promise of specialty pharmaceuticals: Are they worth the price? J Manag Care Pharm. 2008;14(suppl S):S3\u20136.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"388_CR26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/qjmed\/hcu016","volume":"107","author":"HI Hyry","year":"2014","unstructured":"Hyry HI, Stern AD, Cox TM, Roos JCP. Limits on use of health economic assessments for rare diseases. Q J Med. 2014;107(3):241\u20135.","journal-title":"Q J Med"},{"key":"388_CR27","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/hec.1414","volume":"18","author":"C Green","year":"2009","unstructured":"Green C, Gerard K. Exploring the social value of health care interventions: a stated preference discrete choice experiment. Health Econ. 2009;18:951\u201376.","journal-title":"Health Econ"},{"key":"388_CR28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S1744133110000344","volume":"6","author":"M Mentzakis","year":"2011","unstructured":"Mentzakis M, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law. 2011;6:405\u201333.","journal-title":"Health Econ Policy Law"},{"key":"388_CR29","unstructured":"Ministry of Health Republic of Poland. http:\/\/www.mz.gov.pl\/aktualnosci\/swiatowy-dzien-chorob-rzadkich . Accessed June 2014."},{"key":"388_CR30","unstructured":"2012 EUCERD report on the state of the art of rare disease activities in Italy. Available from: http:\/\/www.eucerd.eu\/?post_type=document&p=1494 . Accessed June 2014."},{"key":"388_CR31","unstructured":"National Institute for Health and Care Excellence. Interim Methods of the Highly Specialised Technologies Programme, May 2013. http:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-highly-specialised-technologies-guidance\/Highly-Specialised-Technologies-Interim-methods-and-process-statements.pdf . Accessed January 2015."},{"key":"388_CR32","unstructured":"The Scottish Government, Medicines fund, 2013. http:\/\/www.scotland.gov.uk\/news\/releases\/2013\/01\/medicines-fund14012013 . Accessed November 2014."},{"key":"388_CR33","unstructured":"The Australian Government, Department of Health. Life Saving Drugs Program Criteria and Conditions, April 2013. http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/lsdp-criteria . Accessed January 2015."},{"key":"388_CR34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1750-1172-7-74","volume":"7","author":"W Hughes-Wilson","year":"2012","unstructured":"Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.","journal-title":"Orphanet J Rare Dis"},{"issue":"7523","key":"388_CR35","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/bmj.331.7523.1016","volume":"331","author":"C McCabe","year":"2005","unstructured":"McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331(7523):1016\u20139.","journal-title":"BMJ"},{"key":"388_CR36","unstructured":"National Institute for Health and Clinical Excellence (NICE). Appraising Orphan Drugs, DRAFT v3. http:\/\/www.publications.parliament.uk\/pa\/cm201213\/cmselect\/cmhealth\/782\/782vw.pdf . Accessed October 2014."},{"issue":"2","key":"388_CR37","first-page":"16","volume":"14","author":"MF Drummond","year":"2007","unstructured":"Drummond MF. Challenges in the economic evaluation of orphan drugs, Pharmaceutical policy. Eurohealth. 2007;14(2):16\u20137.","journal-title":"Eurohealth"},{"issue":"1","key":"388_CR38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307051550","volume":"23","author":"MF Drummond","year":"2007","unstructured":"Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36\u201342.","journal-title":"Int J Technol Assess Health Care"},{"key":"388_CR39","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2165\/00019053-200119110-00004","volume":"19","author":"B George","year":"2001","unstructured":"George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision-making: evidences from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001;19:1103\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"388_CR40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/14737167.2014.906903","volume":"14","author":"S Simoens","year":"2014","unstructured":"Simoens S. Health technologies for rare diseases: does conventional HTA still apply? Expert Rev Pharmacoecon Outcomes Res. 2014;14(3):315\u20137.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"388_CR41","unstructured":"National Institute for Health and Care Excellence. Interim, process and methods of the highly specialized technologies programme. 2013. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/niceguidance\/nice-highly-specialised-technologies-guidance . Accessed June 2014."},{"key":"388_CR42","volume-title":"Multi-criteria decision analysis to value orphan medicines","author":"J Sussex","year":"2013","unstructured":"Sussex J, Rollet PM, Garau M, Schmitt C, Kent A, Hutchings A. Multi-criteria decision analysis to value orphan medicines. London: Office of Health Economics; 2013."},{"key":"388_CR43","unstructured":"National Institute for Health and Clinical Excellence NICE Citizens council report \u2013 report 4: Ultra orphan drugs. London, November 2004. https:\/\/www.nice.org.uk\/Media\/Default\/Get-involved\/Citizens-Council\/Reports\/CCReport04UltraOrphanDrugs.pdf . Accessed October 2014."},{"key":"388_CR44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"388_CR45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hast.12","volume":"42","author":"EA Largent","year":"2012","unstructured":"Largent EA, Pearson SD. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012; 42(1):27\u201334.","journal-title":"Hastings Cent Rep"},{"key":"388_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40258-012-0004-y","volume":"11","author":"S Simoens","year":"2013","unstructured":"Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-Effectiveness Assessment of Orphan Drugs. Appl Health Econ Health Policy. 2013;11:1\u20133.","journal-title":"Appl Health Econ Health Policy"},{"issue":"3\u20134","key":"388_CR47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2478\/folmed-2013-0032","volume":"55","author":"GG Iskrov","year":"2013","unstructured":"Iskrov GG, Raycheva RD, Stefanov RS. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs. Folia Med (Plovdiv). 2013;55(3\u20134):80\u20136.","journal-title":"Folia Med (Plovdiv)"},{"key":"388_CR48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.healthpol.2010.09.008","volume":"100","author":"ZRS Rosenberg-Yunger","year":"2011","unstructured":"Rosenberg-Yunger ZRS, Daar AS, Thorsteinsdottir H, Martin DK. Priority setting for orphan drugs: an international comparision. Health Policy. 2011;100:25\u201334.","journal-title":"Health Policy"},{"issue":"Suppl 3","key":"388_CR49","doi-asserted-by":"crossref","first-page":"S774","DOI":"10.1007\/s11606-014-2885-y","volume":"29","author":"E Winquist","year":"2014","unstructured":"Winquist E, Coyle D, Clarke JTR, Evans GA, Seager C, Chan W. Application of a policy framework for the public funding of drugs for rare diseases. J Gen Intern Med. 2014;29 Suppl 3:S774\u20139.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"388_CR50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00019053-200624040-00001","volume":"24","author":"D Hughes","year":"2006","unstructured":"Hughes D. Rationing of drugs for rare diseases. Pharmacoeconomics. 2006;24(4):315\u20136.","journal-title":"Pharmacoeconomics"},{"issue":"7525","key":"388_CR51","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bmj.331.7525.1144-c","volume":"331","author":"M Sheehan","year":"2005","unstructured":"Sheehan M. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness. BMJ. 2005;331(7525):1144\u20135.","journal-title":"BMJ"},{"issue":"9","key":"388_CR52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2471\/BLT.06.031518","volume":"84","author":"P Stolk","year":"2006","unstructured":"Stolk P, Willemen MJ, Leufkens HG. Rare essentials: drugs for rare diseases as essential medicines. Bull World Health Organ. 2006;84(9):745\u201351.","journal-title":"Bull World Health Organ"},{"issue":"11","key":"388_CR53","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/qjmed\/hci128","volume":"98","author":"DA Hughes","year":"2005","unstructured":"Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do They deserve special status for funding? QJM. 2005;98(11):829\u201336.","journal-title":"QJM"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0388-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T21:54:59Z","timestamp":1655243699000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/11\/1\/23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0388-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]},"article-number":"23"}}